FDA Brief

Warning letters Drugs

FDA warning letter to

Generitech Corporation

High riskIssued Mar 1, 2022Posted Apr 12, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Generitech Corporation of Fresno, California over CGMP failures in its topical drug manufacturing and unapproved hydroquinone skin bleaching creams.

What happened

FDA inspected Generitech's drug manufacturing facility at 4967 E Lansing Way, Fresno, California from July 6 to 28, 2021. Investigators found that out-of-specification assay results for salicylic acid in a drug lot were not investigated, that incoming components were not identity tested, that processes and equipment were not validated or qualified, and that shared equipment used for both drugs and cosmetics lacked cleaning validation. FDA also found the company's hydroquinone skin bleaching creams were unapproved new drugs sold without an approved application.

What FDA found

  1. The company did not investigate test results that fell outside its specifications, including salicylic acid assay results of 1.93% and 1.90% on retest.

    21 CFR 211.192
  2. The company did not test each incoming component lot for identity and did not verify the reliability of its suppliers' certificates of analysis.

    21 CFR 211.84(d)(1) and (2)
  3. The company had not completed process performance qualification studies for several products and had not qualified its compounding and filling equipment.

    21 CFR 211.100(a)
  4. The company used the same equipment for drugs and cosmetics and had no cleaning validation to show residues and active ingredients were removed.

    21 CFR 211.67(a)
  5. The hydroquinone skin bleaching creams were unapproved new drugs sold without an FDA-approved application.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  6. The skin bleaching products were misbranded because they do not comply with the requirements for nonprescription drugs marketed without an approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, or to explain any delay and give a completion schedule. FDA also strongly recommends hiring a qualified CGMP consultant.

Who should pay attention

  • brands and retailers buying private-label OTC topical drugs from contract manufacturers
  • companies that run drugs and cosmetics on the same equipment
  • distributors and sellers of hydroquinone skin bleaching products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk